167 related articles for article (PubMed ID: 37158990)
1. Teplizumab Therapy to Delay the Onset of Type 1 Diabetes.
Novograd J; Frishman WH
Cardiol Rev; 2023 May; ():. PubMed ID: 37158990
[TBL] [Abstract][Full Text] [Related]
2. Teplizumab in Type 1 Diabetes Mellitus: An Updated Review.
Thakkar S; Chopra A; Nagendra L; Kalra S; Bhattacharya S
touchREV Endocrinol; 2023 Nov; 19(2):22-30. PubMed ID: 38187075
[TBL] [Abstract][Full Text] [Related]
3. Teplizumab for treatment of type 1 diabetes mellitus.
Skelley JW; Elmore LK; Kyle JA
Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
[TBL] [Abstract][Full Text] [Related]
4. Teplizumab: type 1 diabetes mellitus preventable?
Misra S; Shukla AK
Eur J Clin Pharmacol; 2023 May; 79(5):609-616. PubMed ID: 37004543
[TBL] [Abstract][Full Text] [Related]
5. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function.
Fanaropoulou NM; Tsatsani GC; Koufakis T; Kotsa K
Expert Rev Clin Immunol; 2024 Feb; 20(2):185-196. PubMed ID: 37937833
[TBL] [Abstract][Full Text] [Related]
6. Teplizumab: First Approval.
Keam SJ
Drugs; 2023 Apr; 83(5):439-445. PubMed ID: 36877454
[TBL] [Abstract][Full Text] [Related]
7. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.
Vudattu NK; Herold KC
Expert Opin Biol Ther; 2014 Mar; 14(3):377-85. PubMed ID: 24517093
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Nourelden AZ; Elshanbary AA; El-Sherif L; Benmelouka AY; Rohim HI; Helmy SK; Sayed MK; Ismail A; Ali AS; Ragab KM; Zaazouee MS
Endocr Metab Immune Disord Drug Targets; 2021; 21(10):1895-1904. PubMed ID: 33302842
[TBL] [Abstract][Full Text] [Related]
9. Journey of Teplizumab: A Promising Drug in the Treatment of Type 1 Diabetes Mellitus.
Sharma N; Das DD; Chawla PA
Curr Diabetes Rev; 2024 Jan; ():. PubMed ID: 38279734
[TBL] [Abstract][Full Text] [Related]
10. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
[TBL] [Abstract][Full Text] [Related]
11. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.
Herold KC; Gitelman SE; Gottlieb PA; Knecht LA; Raymond R; Ramos EL
Diabetes Care; 2023 Oct; 46(10):1848-1856. PubMed ID: 37607392
[TBL] [Abstract][Full Text] [Related]
12. Teplizumab (Tzield) to delay onset of type 1 diabetes.
Med Lett Drugs Ther; 2023 Jan; 65(1667):7-8. PubMed ID: 36630581
[No Abstract] [Full Text] [Related]
13. Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab (Tzield™) in Clinical Practice.
Mehta S; Ryabets-Lienhard A; Patel N; Breidbart E; Libman I; Haller MJ; Simmons KM; Sims EK; DiMeglio LA; Gitelman SE; Griffin KJ; Tonyushkina KN
Horm Res Paediatr; 2024 Apr; ():1-12. PubMed ID: 38663372
[TBL] [Abstract][Full Text] [Related]
14. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
Herold KC; Gitelman SE; Willi SM; Gottlieb PA; Waldron-Lynch F; Devine L; Sherr J; Rosenthal SM; Adi S; Jalaludin MY; Michels AW; Dziura J; Bluestone JA
Diabetologia; 2013 Feb; 56(2):391-400. PubMed ID: 23086558
[TBL] [Abstract][Full Text] [Related]
15. Teplizumab therapy for type 1 diabetes.
Masharani UB; Becker J
Expert Opin Biol Ther; 2010 Mar; 10(3):459-65. PubMed ID: 20095914
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials.
Min T; Bain SC
Expert Opin Emerg Drugs; 2023 Mar; 28(1):1-15. PubMed ID: 36896700
[TBL] [Abstract][Full Text] [Related]
17. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
[TBL] [Abstract][Full Text] [Related]
18. Type 1 diabetes pathogenesis - Prevention???
Krishna CS; Srikanta S
Indian J Endocrinol Metab; 2015 Apr; 19(Suppl 1):S58-63. PubMed ID: 25941654
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapies currently in development for the treatment of type 1 diabetes.
Davis IC; Randell J; Davis SN
Expert Opin Investig Drugs; 2015; 24(10):1331-41. PubMed ID: 26364507
[TBL] [Abstract][Full Text] [Related]
20. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
Chatenoud L; Waldmann H
Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
